Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity SarcomasAlexander M.M. Eggermont, Ferdy J. Lejeune, Heimen Schraffordt Koops et al.|Annals of Surgery|1996Cited by 458
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.Alexander M.M. Eggermont, Ferdy J. Lejeune, D. Liénard et al.|Journal of Clinical Oncology|1996Cited by 401
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.Hs Koops, Ferdy J. Lejeune, Maurizio Vaglini et al.|Journal of Clinical Oncology|1998Cited by 246
Superior Outcome of Women With Stage I/II Cutaneous Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer Phase III TrialsArjen Joosse, Esther de Vries, Sandra Collette et al.|Journal of Clinical Oncology|2012Cited by 193
Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastasesD. Liénard, Ferdy J. Lejeune, Alexander M.M. Eggermont et al.|Melanoma Research|1999Cited by 148